There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and quality of life by conducting a systematic review and meta-analysis of randomized controlled trials. Databases from ClinicalTrials.gov, MEDLINE, PsycInfo, PsycArticles, and Cochrane Library were searched from inception to June 2025. Data from seven randomized control trials (both published and unpublished) compared MDMA-AT with low-dose MDMA or placebo control combined with psychotherapy. Identified studies were not included in recent article retractions. Effect sizes were calculated using standardized mean difference for Clinician-Administered PTSD Scale scores and mean difference for secondary measures. MDMA-AT may significantly improve PTSD, dissociation, depression, and functional impairment, compared to controls, but not sleep quality. These results support MDMA-AT for PTSD core symptoms and quality-of-life measures. The evidence, however, is limited by small sample sizes in some studies, challenges with blinding in psychedelic studies, use of non-standardized therapies, and a common sponsor for all trials. While limitations exist, these findings provide evidence for a new emerging treatment option for PTSD.
